These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 33609479)

  • 21. In-vivo brain neuroimaging provides a gateway for integrating biological and clinical biomarkers of Alzheimer's disease.
    Cui J; Zufferey V; Kherif F
    Curr Opin Neurol; 2015 Aug; 28(4):351-7. PubMed ID: 26132531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approach to atypical Alzheimer's disease and case studies of the major subtypes.
    Dickerson BC; McGinnis SM; Xia C; Price BH; Atri A; Murray ME; Mendez MF; Wolk DA
    CNS Spectr; 2017 Dec; 22(6):439-449. PubMed ID: 28196556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.
    Chételat G; Ossenkoppele R; Villemagne VL; Perrotin A; Landeau B; Mézenge F; Jagust WJ; Dore V; Miller BL; Egret S; Seeley WW; van der Flier WM; La Joie R; Ames D; van Berckel BN; Scheltens P; Barkhof F; Rowe CC; Masters CL; de La Sayette V; Bouwman F; Rabinovici GD
    Brain; 2016 Sep; 139(Pt 9):2528-39. PubMed ID: 27357349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration.
    Cousins KAQ; Irwin DJ; Wolk DA; Lee EB; Shaw LMJ; Trojanowski JQ; Da Re F; Gibbons GS; Grossman M; Phillips JS
    Brain; 2020 Jul; 143(7):2295-2311. PubMed ID: 32666090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late-life obesity is a protective factor for prodromal Alzheimer's disease: a longitudinal study.
    Sun Z; Wang ZT; Sun FR; Shen XN; Xu W; Ma YH; Dong Q; Tan L; Yu JT;
    Aging (Albany NY); 2020 Jan; 12(2):2005-2017. PubMed ID: 31986486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Shen L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2013 Sep; 9(5):e111-94. PubMed ID: 23932184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.
    Murray ME; Graff-Radford NR; Ross OA; Petersen RC; Duara R; Dickson DW
    Lancet Neurol; 2011 Sep; 10(9):785-96. PubMed ID: 21802369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.
    Paterson RW; Toombs J; Slattery CF; Nicholas JM; Andreasson U; Magdalinou NK; Blennow K; Warren JD; Mummery CJ; Rossor MN; Lunn MP; Crutch SJ; Fox NC; Zetterberg H; Schott JM
    J Neurol; 2015 Dec; 262(12):2722-30. PubMed ID: 26410752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying individuals with Alzheimer's disease-like brains based on structural imaging in the Human Connectome Project Aging cohort.
    Li B; Jang I; Riphagen J; Almaktoum R; Yochim KM; Ances BM; Bookheimer SY; Salat DH;
    Hum Brain Mapp; 2021 Dec; 42(17):5535-5546. PubMed ID: 34582057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study.
    Whitwell JL; Dickson DW; Murray ME; Weigand SD; Tosakulwong N; Senjem ML; Knopman DS; Boeve BF; Parisi JE; Petersen RC; Jack CR; Josephs KA
    Lancet Neurol; 2012 Oct; 11(10):868-77. PubMed ID: 22951070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.
    Florek L; Tiepolt S; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Luthardt J; Sattler B; Patt M; Hoffmann KT; Villringer A; Classen J; Gertz HJ; Sabri O; Barthel H
    J Alzheimers Dis; 2018; 66(3):1105-1116. PubMed ID: 30400095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The phenotypical core of Alzheimer's disease-related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study.
    Di Stefano F; Kas A; Habert MO; Decazes P; Lamari F; Lista S; Hampel H; Teichmann M
    Alzheimers Dement; 2016 Jul; 12(7):786-95. PubMed ID: 26988428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.